On Wednesday, Aileron Therapeutics Inc (NASDAQ; ALRN) revealed topline data from Cohort 2 of its Phase 1b trial of safety and ...

High-dose LTI-03 (5 mg BID), a Caveolin-1 related peptide, reduced expression of multiple profibrotic proteins in both pathological basal-like cells and fibroblasts and decreased the expression of a ...

Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, reported financial results for the third ...

The first lesion is CB, which is an irreversible lesion that develops by concentric fibrosis in the bronchiole ... bronchioles and alveoli with intra-alveolar buds of granulation tissue resulting ...

[29] These differences are distinguishable by their distribution and pattern of cellularity and fibrosis as well as by their degree of homogeneity. Familial clustering of CFA does occur ...